844 A trispecific ROR1 x CD3 T cell engager mediates in vitro tumor cell killing and in vivo tumor eradication
Chatterjee, Bithi, Snell, Daniel, Hess, Christian, Brock, Matthias, Spiga, Fabio, Simonin, Alexandre, Gunde, Tea, Warmuth, Stefan, Weinert, Christopher, Bassler, Nicole, Kirk, Niels, Schumacher, Nina, Mahler, Dana, Yaman, Yasemin, Bommer, Bettina, Gambino, Giorgio, Giezendanner, Noreen, Kuettner, Benjamin, Flueckiger, Naomi, Heiz, Robin, Wagen, Sandro, Diem, Dania, Zeberer, Julia, Urech, David
Published in Journal for immunotherapy of cancer (01.11.2021)
Published in Journal for immunotherapy of cancer (01.11.2021)
Get full text
Journal Article
Abstract 2276: Preclinical development and mechanism of action studies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate
Snell, Daniel, Gunde, Tea, Warmuth, Stefan, Lichtlen, Peter, Tietz, Julia, Brock, Matthias, Simonin, Alexandre, Hess, Christian, Christopher, Weinert, Heiz, Robin, Flueckiger, Naomi, Zeberer, Julia, Diem, Dania, Mahler, Dana, Morenzoni, Diego, Wickihalder, Belinda, Muntwiler, Simone, Poelderl, Antonia, Kuettner, Benjamin, Wagen, Sandro, Meyer, Sebastian, Egan, Timothy, Urech, David
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
Snell, Daniel, Gunde, Tea, Warmuth, Stefan, Chatterjee, Bithi, Brock, Matthias, Hess, Christian, Johansson, Maria, Simonin, Alexandre, Spiga, Fabio Mario, Weinert, Christopher, Kirk, Niels, Bassler, Nicole, Campos Carrascosa, Lucia, Flückiger, Naomi, Heiz, Robin, Wagen, Sandro, Giezendanner, Noreen, Alberti, Alessandra, Yaman, Yasemin, Mahler, Dana, Diem, Dania, Lichtlen, Peter, Urech, David
Published in Oncoimmunology (31.12.2023)
Published in Oncoimmunology (31.12.2023)
Get full text
Journal Article
Abstract 2871: NM28-2746, a reduced affinity bivalent mesothelin-binding MATCH4 T cell engager, with half-life extension, increases selectivity for killing of mesothelin-overexpressing cells
Chatterjee, Bithi, Hess, Christian, Snell, Daniel, Gunde, Tea, Warmuth, Stefan, Simonin, Alexandre, Brock, Matthias, Spiga, Fabio, Johansson, Maria, Weinert, Christopher, Tietz, Julia, Kirk, Niels, Bassler, Nicole, Mahler, Dana, Diem, Dania, Carrella, Alessandra, Giezendanner, Noreen, Alberti, Alessandra, Gambino, Giorgio, Wickihalder, Belinda, Bommer, Bettina, Muntwiler, Simone, Yaman, Yasemin, Flueckiger, Naomi, Heiz, Robin, Wagen, Sandro, Urech, David
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article
Abstract 2870: Dose selection investigations and combination strategies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate
Snell, Daniel, Gunde, Tea, Warmuth, Stefan, Lichtlen, Peter, Liu, Linlin, Teng, Shu-wen, Zhang, Lan, Pan, ChaoHsuan, Li, Peiqi, Tietz, Julia, Brock, Matthias, Simonim, Alexandre, Hess, Christian, Weinert, Christopher, Johansson, Maria, Chatterjeee, Bithi, Bassler, Nicole, Kirk, Niels, Mendes, Catia, Heiz, Robin, Flueckiger, Naomi, Diem, Dania, Mahler, Dana, Wickihalder, Belinda, Muntwiler, Simone, Wagen, Sandro, vom Baur, Elmar, Tse, Archie N., Urech, David
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article